Breaking News, Collaborations & Alliances

Neurimmune Expands ATTR-CM Collaboration with AstraZeneca

Enters into an exclusive global collaboration and license agreement to develop NI009, a fibril depleter for AL amyloidosis.

Author Image

By: Charlie Sternberg

Associate Editor

Neurimmune has expanded its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion (an AstraZeneca company) by entering into an exclusive global collaboration and license agreement to develop NI009, a preclinical human monoclonal antibody designed to target and deplete lambda light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis. AL amyloidosis is a rare, systemic and progressive disorder caused by defective plasma cells in the bo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters